Novartis AG - Depositary Receipt (Common Stock)
DE ˙ DB ˙ US66987V1098
121,00 € 0,00 (0,00%)
2026-06-04
PREZZO DELLE AZIONI
SecurityDE:NOTA / Novartis AG - Depositary Receipt (Common Stock)
InstitutionKeudell/Morrison Wealth Management
Latest Disclosed Ownership2,058 shares
Latest Disclosed Value $ 314,360
Keudell/Morrison Wealth Management reports 2.49% increase in ownership of NOTA / Novartis AG - Depositary Receipt (Common Stock)

On April 20, 2026 - Keudell/Morrison Wealth Management filed a 13F-HR form disclosing ownership of 2,058 shares of Novartis AG - Depositary Receipt (Common Stock) (DE:NOTA) valued at $264,453 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 6, 2026 disclosing 2,008 shares of Novartis AG - Depositary Receipt (Common Stock). This represents a change in shares of 2.49% during the quarter. The current value of the position is $249,018 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-20 2026-03-31 13F NOVARTIS SPONSORED ADR 66987V109 2,058 50 2.49 314 13.77 0.0643
2026-02-06 2025-12-31 13F NOVARTIS SPONSORED ADR 66987V109 2,008 -820 -29.00 277 -19.30 0.0582
2025-07-22 2025-06-30 13F NOVARTIS SPONSORED ADR 66987V109 2,828 0 0.00 342 8.57 0.0759
2025-04-23 2025-03-31 13F NOVARTIS SPONSORED ADR 66987V109 2,828 104 3.82 315 18.87 0.0744
2025-01-23 2024-12-31 13F NOVARTIS SPONSORED ADR 66987V109 2,724 7 0.26 265 -15.06 0.0691
2024-10-31 2024-09-30 13F NOVARTIS SPONSORED ADR 66987V109 2,717 -74 -2.65 313 5.05 0.0848
2024-07-16 2024-06-30 13F NOVARTIS SPONSORED ADR 66987V109 2,791 -126 -4.32 297 5.32 0.0869
2024-05-07 2024-03-31 13F NOVARTIS SPONSORED ADR 66987V109 2,917 -241 -7.63 282 -11.32 0.0854
2024-02-14 2023-12-31 13F NOVARTIS SPONSORED ADR 66987V109 3,158 16 0.51 319 -0.62 0.1052
2023-10-18 2023-09-30 13F NOVARTIS SPONSORED ADR 66987V109 3,142 -39 -1.23 320 0.00 0.0976
2023-07-20 2023-06-30 13F NOVARTIS SPONSORED ADR 66987V109 3,181 -98 -2.99 321 6.31 0.0925
2023-04-18 2023-03-31 13F NOVARTIS SPONSORED ADR 66987V109 3,279 0 0.00 302 1.35 0.0889
2023-01-20 2022-12-31 13F NOVARTIS SPONSORED ADR 66987V109 3,279 -90 -2.67 297 16.02 0.0955
2022-10-12 2022-09-30 13F NOVARTIS SPONSORED ADR 66987V109 3,369 163 5.08 256 -5.54 0.0958
2022-07-18 2022-06-30 13F NOVARTIS SPONSORED ADR 66987V109 3,206 -912 -22.15 271 -24.93 0.0985
2022-04-18 2022-03-31 13F NOVARTIS SPONSORED ADR 66987V109 4,118 327 8.63 361 8.73 0.1509
2022-02-08 2021-12-31 13F NOVARTIS SPONSORED ADR 66987V109 3,791 -156 -3.95 332 2.79 0.1311
2021-12-08 2021-09-30 13F/A-1 NOVARTIS SPONSORED ADR 66987V109 3,947 268 7.28 323 -3.87 0.1385
2021-10-20 2021-09-30 13F NOVARTIS SPONSORED ADR 66987V109 3,947 268 323 0.1388
2021-07-13 2021-06-30 13F NOVARTIS SPONSORED ADR 66987V109 3,679 179 5.11 336 12.37 0.1839
2021-04-13 2021-03-31 13F NOVARTIS SPONSORED ADR 66987V109 3,500 43 1.24 299 -8.28 0.1735
2021-02-12 2020-12-31 13F NOVARTIS SPONSORED ADR 66987V109 3,457 -57 -1.62 326 6.54 0.2070
2020-10-20 2020-09-30 13F NOVARTIS SPONSORED ADR 66987V109 3,514 -309 -8.08 306 -8.38 0.1967
2020-07-14 2020-06-30 13F NOVARTIS SPONSORED ADR 66987V109 3,823 643 20.22 334 27.48 0.2762
2020-04-20 2020-03-31 13F NOVARTIS A G SPONSORED ADR 66987V109 3,180 821 34.80 262 17.49 0.2563
2020-01-29 2019-12-31 13F NOVARTIS A G SPONSORED ADR 66987V109 2,359 0 0.00 223 8.78 0.1542
2019-11-13 2019-09-30 13F NOVARTIS A G SPONSORED ADR 66987V109 2,359 0 0.00 205 -1.91 0.1691
2019-08-23 2019-06-30 13F/A-1 NOVARTIS A G SPONSORED ADR 66987V109 2,359 100 4.43 209 -3.69 0.1830
2019-08-21 2019-03-31 13F NOVARTIS A G SPONSORED ADR 66987V109 2,259 2,259 217 0.1909
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.